Effect of Febuxostat on Endothelial Dysfunction in Hemodialysis Patients. (NCT02866214) | Clinical Trial Compass
CompletedPhase 2/3
Effect of Febuxostat on Endothelial Dysfunction in Hemodialysis Patients.
57 participantsStarted 2016-08
Plain-language summary
The Purpose of this study is to determine if the Febuxostat has an effect on endothelial dysfunction on hemodialysis patients.
Who can participate
Age range18 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Outpatients on maintenance hemodialysis.
* Age from 18-70 years old.
* Serum Uric Acid level 7.0 mg/dL or more.
* Stable clinical condition (no hospitalization in the previous 3 months)
* Informed consent in accordance with the Declaration of Helsinki.
Exclusion Criteria:
* Current urate-lowering therapy. (allopurinol, probenecid, bucolome, febuxostat)
* History of hypersensitivity to febuxostat.
* Current treatment with mercaptopurine, azathioprine, pyrazinamide, or ethambutol.
* Participant in an another clinical trial within the past 4 weeks.
* Judged to be unsuitable as a subject by the attending physician